SDZ 208-912

• Description :

  SDZ 208-912 is a dual-action 5-HT1A/2 receptor agonist and dopamine D1 receptor antagonist. SDZ 208-912 exhibits partial dopamine agonism and atypical neurosedative effects in rodent models. SDZ 208-912 can be used in research on neurological disorders such as schizophrenia[1].

• UNSPSC :

  12352005

• Target :

  5-HT Receptor; Dopamine Receptor

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Neurological Disease

• Smiles :

  ClC1=C2C3=C(N1)C=CC=C3[C@]4([H])[C@@](N(C[C@H](C4)NC(C(C)(C)C)=O)C)([H])C2

• Molecular Formula :

  C20H26ClN3O

• Molecular Weight :

  359.89

• References & Citations :

  [1]Coward DM, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 1990 Jan;252 (1) :279-85.|[2]Coward DM, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 1990 Jan;252 (1) :279-85.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [101000-49-1]